3 High Growth Stocks Investors May Be Missing Right Now

Global markets are wrestling with higher energy prices, sticky inflation and shifting rate expectations across the US, UK and Eurozone. In this kind of backdrop, investors often look for companies that can grow earnings even when the macro story feels messy. The Healthy high growth potential screener focuses on stocks that analysts expect to deliver strong earnings growth over the next 3 years and that also sit in an acceptable financial position. This article highlights 3 of the best stocks from that screener so you can see how this theme might fit alongside your existing holdings.

Alignment Healthcare (ALHC)

Overview: Alignment Healthcare runs a Medicare Advantage platform that designs tailored health plans for seniors in the US, combining medical coverage with care management and digital tools. The company focuses on giving older adults more coordinated, data driven care while working closely with healthcare providers.

Market Cap: US$3.1b

Alignment Healthcare sits at the intersection of an aging US population and growing demand for Medicare Advantage plans, with analysts highlighting its position as membership and technology driven care models scale. The company’s proprietary data platform and automation are aimed at lowering medical costs and improving margins, while recent results show rising membership and higher full year revenue guidance even as management reinvests in new markets. At the same time, investors need to weigh meaningful risks, including whistleblower lawsuits, pressure on star ratings, tighter Medicare rules and a high current P/E that leaves the stock sensitive to any earnings disappointment.

Alignment Healthcare’s membership and data engine could be telling a more ambitious earnings story than the headline P/E suggests. Get the analyst forecasts for Alignment Healthcare and see what risk might be hiding in the forecasts

Corcept Therapeutics (CORT)

Overview: Corcept Therapeutics is a US biopharmaceutical company that develops drugs targeting disorders linked to the hormone cortisol, including Cushing’s syndrome, certain cancers and metabolic and neurologic conditions. Its products and late stage pipeline focus on selective cortisol modulators that aim to treat severe diseases where current options are limited.

Market Cap: US$12.8b

Corcept Therapeutics is drawing attention because it is moving from dependence on a single Cushing’s syndrome drug into a broader endocrine and oncology franchise supported by Lifyorli’s US launch in platinum resistant ovarian cancer and a resubmitted FDA filing for relacorilant in Cushing’s. Analysts expect earnings and revenue growth well above the wider US market, yet the stock already trades on a rich P/S multiple with price targets suggesting only moderate upside, so expectations are high. Heavy reliance on Korlym and its authorized generic, ongoing patent disputes and pricing pressure remain key watchpoints. For investors comfortable with regulatory and legal risk, Corcept represents a combination of experienced governance, published growth forecasts and a pipeline that could further reshape the story if additional approvals occur.

Corcept Therapeutics sits at the crossroads of high expectations and a widening drug portfolio, yet the full story is not in the share price. Tap into the analyst forecasts for Corcept Therapeutics to see what the market might be missing

Coursera (COUR)

Overview: Coursera is an online learning company that partners with universities, employers and governments to offer courses, professional certificates and full degrees in areas such as business, technology and data science to learners worldwide. Its platform serves both individual subscribers and large organizations that need workforce training and skills development at scale.

Operations: Coursera generates about US$549.9m from its Consumer segment, including degrees, and US$335.5m from its Enterprise segment that sells learning solutions to businesses, campuses and governments.

Market Cap: US$1.5b

Coursera provides exposure to the shift toward online, job focused education, with forecasts pointing to strong revenue growth of about 28% a year and earnings growth that moves the company from losses to expected profitability within 3 years. The stock screens as deeply discounted to estimated fair value. However, recent Q2 2026 results showed that pursuing growth has hurt margins and free cash flow, and management is still relatively new while shareholder dilution has been heavy. If Coursera can improve conversion from free to paid users, execute on its AI learning plans and steadily lift margins, the gap between today’s valuation and the long term earnings story could become very important for investors who are willing to accept higher risk.

Coursera’s shift from heavy losses toward expected profitability with strong forecast growth suggests the current share price may not reflect the full story. Read the analyst forecasts for Coursera to see what could change that faster than many expect.

The three stocks in this article are just a starting point. The full Healthy high growth potential screen surfaces 1,503 more companies that analysts expect to grow earnings and that also pass financial health checks through the Healthy high growth potential screener. Use Simply Wall St to identify, analyze and filter for the specific catalysts and narratives that matter to you so you can focus on the highest conviction ideas in minutes.

Take Control of Your Investment Journey

If Alignment Healthcare or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Ideas Beyond Today?

Fresh breakouts and quiet momentum often fly under the radar for now. Screens age quickly as prices move and sentiment shifts, so review these curated ideas before the crowd.

• Spot cash rich companies that hold up when others wobble by scanning the list of solid balance sheet and fundamentals (45 results) and see which businesses still look robust while it matters.
• Observe structural shifts in automation and manufacturing by checking the 36 robotics and automation stocks where carefully filtered operators could be building momentum before headlines catch up.
• Explore potential infrastructure developments by using the 35 power grid technology and infrastructure stocks and map out which companies may stand to benefit if spending accelerates.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com